Immuneering Announces Closing of $25 Million Private Placement
Immuneering (Nasdaq: IMRX), a clinical-stage oncology company, has successfully closed a $25 million private placement with institutional and accredited investors. The transaction included the sale of 6,329,113 unregistered shares of Class A common stock at $3.95 per share, along with warrants to purchase 2,848,096 additional shares at $5.50 per share.
The offering also included pre-funded warrants at $3.949 per share. The purchase warrants have a five-year exercise period following registration. Leerink Partners served as financial advisor for the placement, which was conducted as a private transaction under Securities Act regulations.
Immuneering (Nasdaq: IMRX), una società oncologica in fase clinica, ha completato con successo un collocamento privato da 25 milioni di dollari con investitori istituzionali e accreditati. L'operazione ha incluso la vendita di 6.329.113 azioni non registrate di azioni ordinarie di Classe A a 3,95 $ per azione, insieme a warrant per l'acquisto di altre 2.848.096 azioni a 5,50 $ per azione.
L'offerta comprendeva anche warrant pre-finanziati a 3,949 $ per azione. I warrant di acquisto hanno un periodo di esercizio di cinque anni successivo alla registrazione. Leerink Partners ha agito come consulente finanziario per il collocamento, che è stato effettuato come operazione privata ai sensi delle normative del Securities Act.
Immuneering (Nasdaq: IMRX), una compañía oncológica en fase clínica, ha cerrado con éxito una colocación privada de 25 millones de dólares con inversores institucionales y acreditados. La transacción incluyó la venta de 6.329.113 acciones no registradas de acciones ordinarias Clase A a 3,95 $ por acción, junto con warrants para comprar 2.848.096 acciones adicionales a 5,50 $ por acción.
La oferta también incluyó warrants prefinanciados a 3,949 $ por acción. Los warrants de compra tienen un periodo de ejercicio de cinco años tras la registración. Leerink Partners actuó como asesor financiero del colocamiento, que se realizó como una transacción privada conforme a las regulaciones del Securities Act.
Immuneering (나스닥: IMRX)는 임상 단계의 종양학 회사로서 기관 투자자 및 공인 투자자들과 함께 2,500만 달러의 사모 발행을 성공적으로 마감했습니다. 거래에는 클래스 A 보통주 6,329,113주(미등록)를 주당 3.95달러에 판매하고, 추가 2,848,096주를 주당 5.50달러에 매수할 수 있는 워런트를 포함했습니다.
이번 공모에는 주당 3.949달러의 선납 워런트도 포함되었습니다. 매수 워런트는 등록 후 5년간의 행사 기간을 가집니다. Leerink Partners는 해당 사모 발행의 재무 자문을 맡았으며, 이 거래는 증권법 규정에 따라 사모 방식으로 진행되었습니다.
Immuneering (Nasdaq: IMRX), une société d'oncologie en phase clinique, a clos avec succès un placement privé de 25 millions de dollars auprès d'investisseurs institutionnels et accrédités. La transaction comprenait la vente de 6 329 113 actions non enregistrées d'actions ordinaires de classe A au prix de 3,95 $ par action, ainsi que des bons de souscription permettant d'acheter 2 848 096 actions supplémentaires à 5,50 $ par action.
L'offre comprenait également des bons préfinancés à 3,949 $ par action. Les bons d'achat bénéficient d'une période d'exercice de cinq ans après l'enregistrement. Leerink Partners a agi en tant que conseiller financier pour le placement, qui a été réalisé comme une transaction privée conformément aux réglementations du Securities Act.
Immuneering (NASDAQ: IMRX), ein klinisch tätiges Onkologieunternehmen, hat eine Privatplatzierung über 25 Millionen US-Dollar mit institutionellen und akkreditierten Investoren erfolgreich abgeschlossen. Die Transaktion umfasste den Verkauf von 6.329.113 nicht registrierten Aktien der Klasse A-Stammaktien zu 3,95 $ pro Aktie sowie Warrants zum Erwerb von weiteren 2.848.096 Aktien zu 5,50 $ pro Aktie.
Das Angebot beinhaltete außerdem vorfinanzierte Warrants zu 3,949 $ pro Aktie. Die Kaufwarrants haben nach der Registrierung eine Ausübungsfrist von fünf Jahren. Leerink Partners fungierte als Finanzberater für die Platzierung, die als Privattransaktion nach den Vorschriften des Securities Act durchgeführt wurde.
- Secured $25 million in gross proceeds to strengthen balance sheet
- Attracted top-tier institutional investors showing confidence in company
- Warrants provide potential for additional future funding at $5.50 per share
- Potential dilution for existing shareholders
- Shares priced at $3.95 represents a discount to market price
- Additional dilution possible if warrants are exercised
Insights
Immuneering secured critical $25M funding through private placement at $3.95/share, strengthening its financial position for oncology clinical development.
Immuneering Corporation has successfully closed a
The deal includes pre-funded warrants for certain investors with a nominal exercise price of
This financing strengthens Immuneering's balance sheet without the typical dilution of a public offering, though the company will need to register these shares for resale as part of the investors' registration rights. The private placement approach allows Immuneering to selectively bring in qualified investors while avoiding market volatility associated with public offerings. Leerink Partners served as financial advisor for the transaction.
For a clinical-stage oncology company, this capital infusion is significant as it provides runway to advance its pipeline through critical development milestones. The
CAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the closing of its previously announced private placement. The private placement was made to top-tier institutional and accredited investors, for total up front gross proceeds of approximately
Immuneering sold: (i) an aggregate of 6,329,113 unregistered shares of the company’s Class A common stock at a purchase price of
The offer and sale of the securities was made in a transaction not involving a public offering and the securities have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.
Leerink Partners acted as a financial advisor to Immuneering for the private placement.
This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or other jurisdiction.
About Immuneering Corporation
Immuneering is a clinical-stage oncology company focused on keeping cancer patients alive. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors. Immuneering’s lead product candidate, atebimetinib (IMM-1-104), is an oral, once-daily Deep Cyclic Inhibitor of MEK designed to improve durability and tolerability, and expand indications to include MAPK pathway-driven tumors such as most pancreatic cancers. Atebimetinib is currently in a Phase 2a trial in patients with advanced solid tumors including pancreatic cancer. The Company’s development pipeline also includes early-stage programs. For more information, please visit www.immuneering.com.
Forward-Looking Statements
This press release contains forward-looking statements, including within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding: our plans to develop, manufacture and commercialize our product candidates; the treatment potential of atebimetinib, alone or in combination with other agents, including modified Gemcitabine/nab-paclitaxel (mGnP); and the expected amount and use of proceeds from this financing.
These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the risks inherent in oncology drug research and development, including target discovery, target validation, lead compound identification, and lead compound optimization; we have incurred significant losses, are not currently profitable and may never become profitable; our projected cash runway; our need for additional funding and ability to continue as a going concern; our unproven approach to therapeutic intervention; our ability to address regulatory questions and the uncertainties relating to regulatory filings, reviews and approvals; the lengthy, expensive, and uncertain process of clinical drug development, including potential delays in or failure to obtain regulatory approvals; our reliance on third parties and collaborators to conduct our clinical trials, manufacture our product candidates, and develop and commercialize our product candidates, if approved; failure to compete successfully against other drug companies; protection of our proprietary technology and the confidentiality of our trade secrets; potential lawsuits for, or claims of, infringement of third-party intellectual property or challenges to the ownership of our intellectual property; our patents being found invalid or unenforceable; costs and resources of operating as a public company; and unfavorable or no analyst research or reports.
These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the three months ended June 30, 2025, and our other reports filed with the U.S. Securities and Exchange Commission, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Media Contact:
Gina Nugent
Gina.nugent.external@immuneering.com
Investor Contact:
Laurence Watts
619-916-7620
laurence@newstreetir.com
FAQ
What is the size of Immuneering's (IMRX) private placement announced in August 2025?
What is the share price for Immuneering's (IMRX) private placement?
How many shares did Immuneering (IMRX) sell in the private placement?
What is the exercise period for the warrants issued in Immuneering's (IMRX) private placement?
Who acted as financial advisor for Immuneering's (IMRX) private placement?
